IPP Bureau
Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland
By IPP Bureau - August 13, 2024
This project is supported by the Irish Government through IDA Ireland
Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer
By IPP Bureau - August 13, 2024
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr
By IPP Bureau - August 13, 2024
Morepen Labs successfully raised Rs. 200 Crore through QIP
Lupin Q1 FY25 profit up 77% at Rs. 801 Cr
By IPP Bureau - August 12, 2024
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Novo Nordisk's H1 sales increased by 24% in Danish kroner
By IPP Bureau - August 12, 2024
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Wockhardt Q1 FY25 revenue up 14%
By IPP Bureau - August 12, 2024
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr
By IPP Bureau - August 12, 2024
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr
By IPP Bureau - August 12, 2024
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Caplin Point announces completion of unannounced USFDA inspection
By IPP Bureau - August 11, 2024
The inspection was concluded with zero observations
Caplin Point listed on Forbes Asia’s “200 Best under a Billion” for 2024
By IPP Bureau - August 11, 2024
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Zydus receives final approval from USFDA for Valbenazine Capsules
By IPP Bureau - August 11, 2024
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
Zydus Lifesciences Q1 FY25 revenue up 21% YoY to reach Rs. 6,207.5 Cr
By IPP Bureau - August 11, 2024
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Health Ministry launches 2nd phase of Mass Drug Administration Campaign 2024 to eliminate Lymphatic Filariasis
By IPP Bureau - August 11, 2024
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr
By IPP Bureau - August 11, 2024
Our centers are performing as expected or even better
Merck to acquire investigational B-Cell depletion therapy from Curon Biopharmaceutical
By IPP Bureau - August 11, 2024
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
